These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 17559599)
21. Prospective 6-month follow-up of patients prescribed risperidone long-acting injection: factors predicting favourable outcome. Taylor DM; Young C; Patel MX Int J Neuropsychopharmacol; 2006 Dec; 9(6):685-94. PubMed ID: 16939663 [TBL] [Abstract][Full Text] [Related]
22. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for first-episode schizophrenia patients: initial adherence outcome. Weiden PJ; Schooler NR; Weedon JC; Elmouchtari A; Sunakawa A; Goldfinger SM J Clin Psychiatry; 2009 Oct; 70(10):1397-406. PubMed ID: 19906343 [TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia : a 12- and 24-month follow-up from the e-STAR database in Spain. Olivares JM; Rodriguez-Martinez A; Burón JA; Alonso-Escolano D; Rodriguez-Morales A; Appl Health Econ Health Policy; 2008; 6(1):41-53. PubMed ID: 18774869 [TBL] [Abstract][Full Text] [Related]
24. Diffusion of a new drug: a comparative analysis of adoption, treatment complexity, and persistence of risperidone long-acting injectable therapy in the Netherlands. Pechlivanoglou P; Vehof J; van Agthoven M; de Jong-van den Berg LT; Postma MJ Clin Ther; 2010 Jan; 32(1):108-18. PubMed ID: 20171417 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of health services use following the initiation of risperidone long-acting therapy among schizophrenia patients in the veterans health administration. Ren XS; Crivera C; Sikirica M; Dirani R; Qian S; Kazis LE J Clin Pharm Ther; 2011 Jun; 36(3):383-9. PubMed ID: 21062329 [TBL] [Abstract][Full Text] [Related]
26. The combined use of risperidone long-acting injection and clozapine in patients with schizophrenia non-adherent to clozapine: a case series. Se Hyun Kim ; Dong Chung Jung ; Yong Min Ahn ; Yong Sik Kim J Psychopharmacol; 2010 Jul; 24(7):981-6. PubMed ID: 19942641 [TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Edwards NC; Locklear JC; Rupnow MF; Diamond RJ Pharmacoeconomics; 2005; 23 Suppl 1():75-89. PubMed ID: 16416763 [TBL] [Abstract][Full Text] [Related]
29. Health resource utilization associated with switching to risperidone long-acting injection. Young CL; Taylor DM Acta Psychiatr Scand; 2006 Jul; 114(1):14-20. PubMed ID: 16774656 [TBL] [Abstract][Full Text] [Related]
30. Experience with injectable long-acting risperidone in long-term therapy after an acute episode of schizophrenia: the SPHERE Study. De la Gándara J; San Molina L; Rubio G; Rodriguez-Morales A; Hidalgo Borrajo R; Burón JA Expert Rev Neurother; 2009 Oct; 9(10):1463-74. PubMed ID: 19831836 [TBL] [Abstract][Full Text] [Related]
32. Patients in the early phases of schizophrenia and schizoaffective disorders effectively treated with risperidone long-acting injectable. Parellada E; Andrezina R; Milanova V; Glue P; Masiak M; Turner MS; Medori R; Gaebel W J Psychopharmacol; 2005 Sep; 19(5 Suppl):5-14. PubMed ID: 16144781 [TBL] [Abstract][Full Text] [Related]
33. Prospective, open study of long-acting injected risperidone versus oral antipsychotics in 88 chronically psychotic patients. Girardi P; Serafini G; Pompili M; Innamorati M; Tatarelli R; Baldessarini RJ Pharmacopsychiatry; 2010 Mar; 43(2):66-72. PubMed ID: 20099224 [TBL] [Abstract][Full Text] [Related]
34. Long acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR database. Lambert T; Emmerson B; Hustig H; Resseler S; Jacobs A; Butcher B; BMC Psychiatry; 2012 Mar; 12():25. PubMed ID: 22448928 [TBL] [Abstract][Full Text] [Related]
35. [Case of schizophrenia in which depressive and negative symptoms relapsed on switching from oral risperidone to risperidone long-acting injection]. Mori T Seishin Shinkeigaku Zasshi; 2011; 113(10):977-82. PubMed ID: 22187885 [TBL] [Abstract][Full Text] [Related]
36. A six month randomized controlled trial of long acting injectable risperidone 50 and 100mg in treatment resistant schizophrenia. Meltzer HY; Lindenmayer JP; Kwentus J; Share DB; Johnson R; Jayathilake K Schizophr Res; 2014 Apr; 154(1-3):14-22. PubMed ID: 24630262 [TBL] [Abstract][Full Text] [Related]
37. A comparative efficacy and safety study of long-acting risperidone injection and risperidone oral tablets among hospitalized patients: 12-week randomized, single-blind study. Bai YM; Chen TT; Wu B; Hung CH; Lin WK; Hu TM; Lin CY; Chou P Pharmacopsychiatry; 2006 Jul; 39(4):135-41. PubMed ID: 16900609 [TBL] [Abstract][Full Text] [Related]
38. Risperidone long-acting injection (RLAI): the 12-week efficacy and tolerability in Thai patients with chronic schizophrenia. Arunpongpaisal S; Srisurapanont M; Kongsakon R; Kitiwattanagul K; Samanwongthai U J Med Assoc Thai; 2010 Mar; 93(3):343-50. PubMed ID: 20420110 [TBL] [Abstract][Full Text] [Related]
39. Long-acting risperidone vs. placebo in the treatment of hospital inpatients with schizophrenia. Lauriello J; McEvoy JP; Rodriguez S; Bossie CA; Lasser RA Schizophr Res; 2005 Jan; 72(2-3):249-58. PubMed ID: 15560969 [TBL] [Abstract][Full Text] [Related]
40. A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. Lee NY; Kim SH; Cho SJ; Chung YC; Jung IK; Kim CY; Kim DH; Lee DG; Lee YH; Lim WJ; Na YS; Shin SE; Woo JM; Yoon JS; Yoon BH; Ahn YM; Kim YS Int Clin Psychopharmacol; 2014 Sep; 29(5):279-87. PubMed ID: 24583566 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]